Skip to main content

Catalio Capital Management — Portfolio, Page 4

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

132
Companies
$12.7B
Total invested
$93.1M
Avg. check
26
Industries
Biotechnology 15Health Care 14Medical 9Life Science 8Therapeutics 7Oncology 5+20 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 7396 of 132
Haystack Oncology
November 2022

Haystack Oncology enables precision oncology to optimize treatment strategies.

Biotechnology · Baltimore$56.0M Series A
Alentis Therapeutics
November 2024

ALENTIS Therapeutics is a Swiss-French biotech company developing novel therapeutics in advanced liver disease and cancer.

Biotechnology · Allschwil$181.4M Series D
Orasis Pharmaceuticals
October 2024

Orasis Pharmaceuticals is an ophthalmic pharmaceutical company that develops eye drops for the treatment of presbyopia.

Clinical Trials · Ponte Vedra$68.0M Series D
Sanguine
October 2023

Bridging the gap between patients and researchers

Apps · Woburn$6.0M Debt Financing
Immunai
October 2021

Immunai is a biotech company that provides mapping and reprogramming immunology, machine learning, and software engineering.

Analytics · New York$215.0M Series B
AtaiBeckley
October 2025

AtaiBeckley develops innovative mental health treatments that address significant unmet medical needs.

Biotechnology · Berlin$149.5M Post-IPO Equity
Sunbird Bio
October 2024

Sunbird Bio is a diagnostics platform developer that aims to give molecular diagnostics with faster outcomes.

Biotechnology · Singapore$14.0M Venture - Series Unknown
Imperative Care
March 2026

Imperative Care is singularly dedicated to finding meaningful answers to unsolved problems in stroke.

Health Care · Campbell$100.0M Convertible Note
Avava
March 2026

Avava is a Pioneer precision skin therapy to improve the quality of life for patients around the world.

Health Care · Waltham$19.6M Series D
Somethings
February 2026

Somethings is a platform for wellness tailored to young people that links youngsters with qualified mentors.

Health Care · New York$19.2M Series A
Lila Sciences
January 2026

Lila Sciences creates a scientific superintelligence platform and autonomous labs for life sciences, chemistry, and materials science.

Artificial Intelligence (AI) · Cambridge$671K Grant
PrognomiQ
January 2026

PrognomiQ is a biotechnology firm that develops test products to detect early disease detection through the power of multi-omics data.

Biopharma · San Mateo$11.9M Series Unknown
Parabilis Medicines
January 2026

Parabilis Medicines is a Grupo Bugio is a biopharmaceutical firm that specializes in creating medicines.

Biopharma · Cambridge$305.0M Series F
Medra AI
December 2025

Medra AI develops an autonomous scientific experimentation platform that combines robotics with artificial intelligence.

Artificial Intelligence (AI) · San Francisco$52.0M Series A
Hyperfine
November 2025

Hyperfine makes MRI accessible to every patient regardless of income or resources.

Computer · Guilford$3.7M Grant
Freenome
November 2025

Freenome is a biotechnology company developing blood tests for early cancer detection to improve access to routine screening.

Biotechnology · South San Francisco$75.0M Corporate Round
Imbria Pharmaceuticals
November 2025

Imbria Pharmaceuticals is a clinical stage biotechnology company developing novel therapies for cardiometabolic diseases.

Biotechnology · BostonSeries B
Beacon Biosignals
November 2025

Beacon Biosignals is a neurotechnology company that brings precision neuroscience into clinical trials and treatments.

Artificial Intelligence (AI) · Boston$86.0M Series B
Star Therapeutics
October 2025

Star Therapeutics mission is to develop therapies for as many diseases as possible for millions of patients.

Health Care · South San Francisco$125.0M Undisclosed
Cartography Biosciences
October 2025

Cartography is an oncology company that develops cancer immunotherapies that target novel and highly specific tumor antigens.

Biopharma · South San Francisco$67.0M Series B
Volastra Therapeutics
September 2025

Volastra Therapeutics is a biotechnology company developing novel therapies for the treatment of metastatic cancers.

Biotechnology · New York$30.1M Series A
Ensoma
September 2025

Ensomaa is a genomic medicine company that develops on one-time in vivo treatments for immuno-oncology and other therapeutic applications.

Biotechnology · Boston$53.0M Series Unknown
Odyssey Therapeutics
September 2025

Odyssey Therapeutics creates precision immunomodulators and oncology medicines for patients with cancer and inflammatory diseases.

Biotechnology · Cambridge$213.0M Series D
Enveda Biosciences
September 2025

Enveda Biosciences is a biotechnology company that develops novel medications derived from plants.

Biotechnology · Boulder$150.0M Series D

Where Catalio Capital Management invests

Biotechnology15
Health Care14
Medical9
Life Science8
Therapeutics7
Oncology5

About Catalio Capital Management's portfolio

How many companies has Catalio Capital Management invested in?

Catalio Capital Management has invested in 132 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Catalio Capital Management invest in?

Catalio Capital Management's top investment sectors include Biotechnology, Health Care, Medical, Life Science, Therapeutics. The firm invests across 26 different industry categories.

What is Catalio Capital Management's largest investment?

Among tracked funding rounds, Parabilis Medicines received $305.0M in a Series F round. Catalio Capital Management's total known invested capital is $12.7B.

What is the average investment size for Catalio Capital Management?

Catalio Capital Management's average investment size is $93.1M across its portfolio of 132 companies.

What are Catalio Capital Management's most recent investments?

Recent Catalio Capital Management portfolio additions include Haystack Oncology, Alentis Therapeutics, Orasis Pharmaceuticals, Sanguine, Immunai. These companies were founded in 2020 or later.

Reach the founders behind these 132 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →